Protalix's PRX-115 Keeps Uric Acid Below Target for Up to 12 Weeks in Phase 1 Study

• Protalix BioTherapeutics announced Phase 1 results showing higher PRX-115 doses sustained uric acid lowering longer, supporting less frequent dosing for uncontrolled gout.
• The findings will be presented at ACR Convergence on November 10, 2026.
• Treatment was generally well tolerated; one anaphylactic reaction resolved, with no other serious adverse events reported.
• The Phase 2 RELEASE trial tests dosing every four weeks without methotrexate or every eight weeks with methotrexate.
• Top-line results are expected in the second half of 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611090645PR_NEWS_USPR_____IO92331) on November 09, 2026, and is solely responsible for the information contained therein.